Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    mRNA and Oligonucleotide Therapeutics: Emerging Synergies in Genetic Medicine

    MRNA therapies work by introducing synthetic mRNA encoding a therapeutic protein enabling transient protein expression that can replace deficient enzymes stimulate immune responses or facilitate gene editing This additive approach is beneficial for diseases caused by lossoffunction mutations or when temporary protein expression is desired

    Blockchain in Pharma: Strengthening Drug Traceability, Compliance, and Supply Chain Security

    For most of the last decade the European pharmaceutical industry framed supply chain integrity as a packaging problem Put a unique identifier on every pack seal it with an antitampering device check it at the point of dispensing and the falsified medicine threat would be contained Since February that model has been law across the European Union and it has worked better than many sceptics predicte...

    The Top 15 Pharma Blogs and Publications in the World

    To the extent that it is recognized as a vital source of information the pharmaceutical industry relies heavily on credible blogs and publications These platforms not only provide insights into the latest research and trends but also foster discussions that can influence policy and practice within the healthcare sector

    How to Mitigate Operational Risks in the Pharma Industry?

    The operation of the pharmaceutical industry has significant risks with the most probable being operational risks These risks include supply chain interruption regulatory non compliance product defects technological disruption The development of strategies to avoid compromise in operations remains paramount not only in protecting the customers from harm or receiving

    How Pharma 4.0 Is Revolutionizing Drug Manufacturing

    The pharmaceutical industry in the world is experiencing a digital transformation rejuvenated by the advent of Pharma an industry phenomenon that is based on Industry Due to the readjustment of the manufacturing industry to Industry the automation data interchange and intelligent ecosystem the pharmaceutical ecosystem is similarly being reorganized with Pharma technologies Research and develo...

    European Pharmaceutical Legal Frameworks: Compliance, Legislation and Regulatory Obligations

    If youve ever opened the EUs pharmaceutical rulebook and felt your eyes glaze over youre not alone Directives regulations guidelines delegated acts it can feel like reading a legal maze with no exit sign

TOP ARTICLES

  • 4

    How Pharma 4.0 Is Revolutionizing Drug Manufacturing

    Kate Williamson

    Pharma 4.0 is a digital revolution in the pharmaceutical business, which combines AI, IoT, automation, and data analytics to revolutionize drug production. It advances smarter pharmaceutical productio...

press releases Read more...

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

MacroGenics Inc a clinicalstage biopharmaceutical company focused on developing innovative antibodybased therapeutics for the treatment of cancer today announced that the first patient has been dosed in the Phase study of MGC a firstinclass antibodydrug conjugate

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

Legend Biotech Corporation a global leader in cell therapy today announced that the US Food and Drug Administration FDA has cleared the investigational new drug IND application for LB an investigational in vivo CART therapy designed to generate CDCD dualtargeting chimeric antigen receptor T

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Eikon Therapeutics Inc a latestage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs today announced the submission of an Investigational New Drug IND application to the US Food and Drug Administration FDA to evaluate EIK for the t...

Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome

Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWS Read more...

AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials

AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support

Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments

Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments

Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Insitro an AI company unlocking causal human biology to systematically generate highvalue therapeutics to treat grievous illness today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunctionassociated steat...

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize

Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial

Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics